A recent modeling study by Anwari and colleagues, published in BMC Health Services Research, evaluates the cost‑effectiveness and benefit–risk profile of rotavirus vaccination in Afghanistan following its post‑licensure rollout. Researchers employed surveillance data to estimate both economic and health outcomes, accounting for vaccine costs, rotavirus disease burden, and potential adverse events. Their model indicates that the vaccination program is not only cost‑effective—offering strong value for money compared to established thresholds—but also delivers substantial health benefits, preventing numerous cases of severe diarrhea, hospitalizations, and deaths among children.
Beyond demonstrating favorable economic returns, the study highlights a compelling benefit–risk balance. The estimated number of serious adverse events is low relative to the considerable health gains achieved, reinforcing the public health value of sustaining and scaling the program. These findings support continued investment in rotavirus immunization across Afghan provinces and may guide future vaccine policy in similar low- and middle‑income countries. Policymakers and funders can leverage this evidence to enhance coverage and secure resources, ultimately reducing the economic and health burden of rotavirus on vulnerable communities.
Thumbnail image credit: Gavi/2023/Prakhar Deep Jain
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.